Nasolacrimal drainage system implants for drug therapy

1. A method for delivery of a therapeutic agent to an eye, comprising:

placing a lacrimal implant through a punctum and into a canalicular lumen of a patient, the implant comprising: a plug body comprising a drug insert; the drug insert comprising:

a matrix of material;

a therapeutic agent dispersed in the matrix of material; and

a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen, wherein when the implant is inserted into the canalicular lumen an exposed surface of the drug insert is in direct contact with tear fluid to allow diffusion of the therapeutic agent from a surface of the matrix of material to a tear film of the eye.

2. The method according to claim 1 , wherein the therapeutic agent comprises a prostaglandin analogue.

3. The method according to claim 2 , wherein the prostaglandin analogue is selected from the group consisting of latanoprost, bimatoprost, and travoprost.

4. The method according to claim 1 , wherein the matrix of material comprises a non-biodegradable polymer.

5. The method according to claim 4 , wherein the matrix of material comprises silicone or urethane.

6. A method for delivery of a therapeutic agent to an eye, comprising:

placing a lacrimal implant into a punctum of a patient, the implant comprising:

a therapeutic agent;

a body of material that holds the therapeutic agent;

a retention structure configured to retain the body of material near the punctum.

7. The method according to claim 6 , wherein the body of material holds the therapeutic agent in a reservoir and/or a matrix.

8. The method according to claim 7 , wherein the body of material is a matrix comprising polymers selected from protein, hydrogel, polyglycolic acid (PGA), polylactic acid (PLA), poly(L-lactic acid) (PLLA), poly(L-glycolic acid) (PLGA), polyglycolide, poly-L-lactide, poly-D-lactide, poly(amino acids), polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, polyorthoesters, polyhydroxybutyrate, polyanhydride, polyphosphoester, poly(alpha-hydroxy acid) and combinations thereof.

9. The method according to claim 8 , wherein the matrix comprises a hydrogel.

10. The method according to claim 6 , wherein the therapeutic agent comprises a prostaglandin analogue.

11. The method according to claim 10 , wherein the prostaglandin analogue is selected from the group consisting of latanoprost, bimatoprost, and travoprost.

12. The method according to claim 6 , wherein the retention structure is configured to engage a luminal wall of the canalicular lumen to retain the implant within the canalicular lumen.

13. The method according to claim 1 , wherein the therapeutic agent is a thrombin inhibitor, a fibrinolytic agent, a vasospasm inhibitor, a vasodilator, an antimicrobial agents, an antifungal, an antiviral, an anticancer chemotherapeutic agent, an anti-inflammatory agent, a non-steroidal anti-inflammatory agent, a hormonal agent, an immunosuppressive agent, a growth hormone antagonist, a growth factor, an angiogenesis inhibitor, a peptide, a protein, or an enzymes.

14. The method of claim 6 , wherein the therapeutic agent is a thrombin inhibitor, a fibrinolytic agent, a vasospasm inhibitor, a vasodilator, an antimicrobial agents, an antifungal, an antiviral, an anticancer chemotherapeutic agent, an anti-inflammatory agent, a non-steroidal anti-inflammatory agent, a hormonal agent, an immunosuppressive agent, a growth hormone antagonist, a growth factor, an angiogenesis inhibitor, a peptide, a protein, or an enzymes.